Michele M Tana1, Xiongce Zhao2, Alyson Bradshaw2, Mi Sun Moon2, Sandy Page2, Tiffany Turner2, Elenita Rivera2, David E Kleiner3, Theo Heller2. 1. Liver Diseases Branch, Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bldg. 10 Rm. 9B16, Bethesda, MD 20892, USA; Division of Gastroenterology, UCSF Liver Center, University of California, San Francisco, USA. Electronic address: tanam@medsfgh.ucsf.edu. 2. Liver Diseases Branch, Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bldg. 10 Rm. 9B16, Bethesda, MD 20892, USA. 3. National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bldg. 10 Rm. 9B16, Bethesda, MD 20892, USA.
Abstract
BACKGROUND: There are many potential causes of thrombocytopenia in patients with chronic hepatitis C (CHC). AIMS: We sought to determine the association between thrombopoietin (TPO) level, immature platelet fraction (IPF), immunoglobulin G (IgG) level, spleen size, and the platelet count in CHC. METHODS: We studied a consecutive sample of patients enrolled in an observational study at a referral-based research center, excluding subjects based on eligibility criteria. TPO, glycocalicin, and von Willebrand Factor (vWF) levels were determined using stored sera. Hepatic fibrosis was assessed via transient elastography (TE) when available, and clinical laboratory values and radiologic data were obtained from the medical record. We performed analyses of the relationships between independent variables and the platelet count. RESULTS: On univariate analysis, the following variables were significantly associated with the platelet count: age, alanine aminotransferase (ALT), direct bilirubin, total bilirubin, IPF, international normalized ratio (INR), spleen size, vWF, glycocalicin, fibrosis stage on liver biopsy, and TE (P-values all <0.05). A multivariable model determined that imputed TE score, TPO, IPF, and spleen size were independently associated with the platelet count (P-values all<0.05). CONCLUSIONS: The platelet count in CHC is significantly associated with fibrosis, TPO level, IPF, and spleen size. Our findings challenge the proposed mechanism of decreased TPO levels or decreased bone marrow production of platelets as a cause of thrombocytopenia in CHC. Future studies focusing on the effects of fibrosis and splenomegaly on platelets may shed more light on the pathophysiology of thrombocytopenia in patients with CHC.
BACKGROUND: There are many potential causes of thrombocytopenia in patients with chronic hepatitis C (CHC). AIMS: We sought to determine the association between thrombopoietin (TPO) level, immature platelet fraction (IPF), immunoglobulin G (IgG) level, spleen size, and the platelet count in CHC. METHODS: We studied a consecutive sample of patients enrolled in an observational study at a referral-based research center, excluding subjects based on eligibility criteria. TPO, glycocalicin, and von Willebrand Factor (vWF) levels were determined using stored sera. Hepatic fibrosis was assessed via transient elastography (TE) when available, and clinical laboratory values and radiologic data were obtained from the medical record. We performed analyses of the relationships between independent variables and the platelet count. RESULTS: On univariate analysis, the following variables were significantly associated with the platelet count: age, alanine aminotransferase (ALT), direct bilirubin, total bilirubin, IPF, international normalized ratio (INR), spleen size, vWF, glycocalicin, fibrosis stage on liver biopsy, and TE (P-values all <0.05). A multivariable model determined that imputed TE score, TPO, IPF, and spleen size were independently associated with the platelet count (P-values all<0.05). CONCLUSIONS: The platelet count in CHC is significantly associated with fibrosis, TPO level, IPF, and spleen size. Our findings challenge the proposed mechanism of decreased TPO levels or decreased bone marrow production of platelets as a cause of thrombocytopenia in CHC. Future studies focusing on the effects of fibrosis and splenomegaly on platelets may shed more light on the pathophysiology of thrombocytopenia in patients with CHC.
Authors: Simon Panzer; Esther Seel; Markus Brunner; Günther F Körmöczi; Monika Schmid; Peter Ferenci; Markus Peck-Radosavljevic Journal: Eur J Haematol Date: 2006-10-17 Impact factor: 2.997
Authors: Jacob A Udell; Charlie S Wang; Jill Tinmouth; J Mark FitzGerald; Najib T Ayas; David L Simel; Michael Schulzer; Edwin Mak; Eric M Yoshida Journal: JAMA Date: 2012-02-22 Impact factor: 56.272
Authors: Renata Grozovsky; Antonija Jurak Begonja; Kaifeng Liu; Gary Visner; John H Hartwig; Hervé Falet; Karin M Hoffmeister Journal: Nat Med Date: 2014-12-08 Impact factor: 53.440
Authors: Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller Journal: Hepatology Date: 2017-06-26 Impact factor: 17.425
Authors: Rabab O Ali; Mi Sun Moon; Elizabeth C Townsend; Kareen Hill; Grace Y Zhang; Alyson Bradshaw; Hannah Guan; Destanee Hamilton; David E Kleiner; Sungyoung Auh; Christopher Koh; Theo Heller Journal: Dig Dis Sci Date: 2019-08-12 Impact factor: 3.199
Authors: Pallavi Surana; Julian Hercun; Varun Takyar; David E Kleiner; Theo Heller; Christopher Koh Journal: World J Gastrointest Pathophysiol Date: 2021-05-22